detail content area
- Date2019-04-17 13:39
- Update2019-05-03 10:38
KNIH (Korea National Institute of Health)
- 2019 Grant Program
2nd Official Announcement on International Collaborative Research for Tuberculosis
(Sponsored by Korea National Institute of Health, KCDC)
The Korea National Institute of Health (KNIH), a research institute under the Korea Centers for Disease Control and Prevention (KCDC) and the Ministry of Health & Welfare, spares no effort to promote the public’s health through research on infectious and non-infectious diseases.
Tuberculosis (TB) is a preventable and curable disease, but remains a public threat worldwide. One of the global efforts to combat TB is to develop new regimens and drugs to reduce the duration of chemotherapy. Additionally, development of an effective therapy is a central strategy to control TB. Also, reliable biomarkers could provide a driving force behind the development of new treatment strategies because such biomarkers serve as an indicator of successful treatment and enable monitoring of outcomes after treatment completion. In this context, the KNIH has conducted scientific research on biomarkers of showing an earlier response to TB treatment. The purpose of the program is to facilitate international cooperation on clinical research for assessment of biomarkers, thus shortening the period of TB treatment.
2. Project Details
Clinical application and assessment of pathogen-based biomarkers for tuberculosis treatment outcomes
2.2. Project Period
Starting date: 5/dd/2019 (after—), End date: 12/31/2021
- 1st year (5/dd/2019—12/31/2019)
- 2nd year (1/1/2020—12/31/2020)
- 3rd year (1/1/2021—12/31/2021)
The annual fund will be around 90,000 USD (100,000,000 KRW).
TB-high burden countries in Asia (more than 100 people/100,000 population in TB incidence)
2.4. Eligibility of Applicants
Must have a Ph.D. or an MD.
2.5. Research Areas of Focus
● Construction and management of TB cohort study
- Enroll TB patients (around 100 patients per year, with patients with HIV excluded)
- Treatment and periodical observation (pre-treatment and 2w/4w/2m follow-ups) during anti-tuberculosis treatment
- Diagnosis: CXR, sputum microscopy, PCR, culture, phenotype DST (MIC), molecular DST (NGS)
- (a) Treatment and periodical observation (pre-treatment and 2w/4w/2m follow-ups) and (b) confirmation of a relapse after treatment has been completed
- Collection, de-contamination, and preservation of sputum for every visit
- Isolation and preservation of bacteria
- Molecular typing (MIRU VNTR using fragment analysis and spoligotyping recommended)
● Evaluation of NGS-based molecular DST for clinical usefulness (required)
* Scientific or technical skills will be supported through staff training and/or practical method sharing.
Government institute, university, hospital, etc.
4. Reporting System
The application should be written in English.
It is important that the file be saved in the format of MS Word.
5. Key Dates
- Open date April 17, 2019
- Letter of Intent (LOI) & application due date April May 7, 2019
* The LOI and the project proposal should be submitted via e-mail (email@example.com)
A reply confirming your successful submission will be e-mailed in three days.
* Format of documents should be MS Word in English.
- Review due date May 10, 2019
- Result notification (via e-mail) May 14, 2019
Division of Bacterial Disease Research,
Center for Infectious Disease Research, Korea Centers for Disease Control and Prevention, South Korea